Table Info

Table 1.

HER2 immunohistochemistry results in diverse cancers

Variable	N (%) of patients
Age, mean ± SD	67 ± 12.5 years
Gender (N = 499)
Male Female	270 (54%) 229 (46%)
Number of tumor types tested, N	42
Inadequate tissue retrieved	15 (3%)
Source of tissue (N = 499)
Biopsy Surgical resection	329 (66%) 170 (34%)
IHC levels (N = 484)
0 1+ 2+ 3+	209 (43%) 56 (12%) 169 (35%) 50 (10%)
TAT for HER2 expression results (N = 489)	18 (IQR, 11 to 30) days

TAT: turnaround time; SD: standard deviation; IQR: interquartile range

Supplementary materials

The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/1002265_sup_1.pdf.

Declarations

Author contributions

DB, SAW, MJC, CH, BS: Conceptualization. DB, MJC, PJ, CLY, CH, BS, HM, LAP: Methodology. SV: Writing—original draft. DB, AC, SAW, MJC, SV, LAP, DP, HM, PJ, JS, CLY, CH, BS: Writing—review & editing. DB: Visualization. DB, SAW, BS, MJC: supervision. NG, AC, LAP, DP, HM, MJC, PJ, CLY, CH, JS: Investigation. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest

DB has accepted honoraria and/or speaking fees from Astra Zeneca, Amgen, Bristol-Myers Squibb, Takeda, Bayer, Guardant, Roche, Janssen and Merck. The rest of the authors have no conflict of interest.

Ethical approval

The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice, and it was approved by the Institutional REB (108938).

Consent to participate

Prospective consent was obtained from adult oncology patients referred to the London Regional Cancer Program at London Health Sciences Centre for IHC and molecular genetic testing of malignant tissue samples as part of the Precision Oncology at WesteRn University (POWER) study.

Consent to publication

Not applicable.

Availability of data and materials

Data are available on reasonable request.

Funding

This study was made possible through philanthropic donation from the Verspeeten Family to London Health Sciences Center, and through small grant funding from the Medical Oncology Research Fund at Western University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–87. [DOI] [PubMed] [PMC]

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12. [DOI] [PubMed]

King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229:974–6. [DOI] [PubMed]

Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232:1644–6. [DOI] [PubMed]

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82. [DOI] [PubMed]

Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol. 2001;12:S9–13. [DOI] [PubMed]

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al.; DESTINY-Breast01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382:610–21. [DOI] [PubMed] [PMC]

Bang YJ, Cutsem EV, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376:687–97. [DOI] [PubMed]

Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, et al.; MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023;24:496–508. [DOI] [PubMed]

10.

Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al.; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022;386:241–51. [DOI] [PubMed] [PMC]

11.

Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41:3867–72. [DOI] [PubMed]

12.

Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805. [DOI] [PubMed]

13.

Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016;22:4619–25. [DOI] [PubMed] [PMC]

14.

Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol. 2023;8:56–65. [DOI] [PubMed]

15.

Albarrán V, Rosero DI, Chamorro J, Pozas J, San Román M, Barrill AM, et al. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. Int J Mol Sci. 2022;23:12659. [DOI] [PubMed] [PMC]

16.

Friedman CF, D’Souza AA, Tinker AV, Corral E, Gambardella V, Goldman JW, et al. 559P Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial. Ann Oncol. 2022;33:S803–4. [DOI]

17.

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors [Internet]. c2023 [cited 2023 Aug 22]. Available from: https://clinicaltrials.gov/study/NCT05150691

18.

Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee SN, Gonzalez Martin A, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. JCO. 2023;41:LBA3000. [DOI]

19.

Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, et al.; HERIZON-BTC-01 study group. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24:772–82. [DOI] [PubMed]

20.

Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33–48. [DOI] [PubMed]

21.

Hou Y, Nitta H, Li Z. HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept. Cancers (Basel). 2023;15:2664. [DOI] [PubMed] [PMC]

22.

Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:446–64. [DOI] [PubMed]

23.

Zhao S, Zhang Z, Zhan J, Zhao X, Chen X, Xiao L, et al. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med. 2021;19:223. [DOI] [PubMed] [PMC]

24.

Reck M, Ramos J, Tan S, Stinchcombe T. P47.01 SGNTUC-019: Phase 2 Study of Tucatinib and Trastuzumab in Solid Tumors: Lung Cancer Cohorts (Clinical Trial in Progress). J Thorac Oncol. 2021;16:S1096. [DOI]

25.

Meric-Bernstam F, Hanna D, Beeram M, Lee KW, Kang YK, Chaves J, et al. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. Ann Oncol. 2019;30:v167–8. [DOI]

26.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102. [DOI] [PubMed] [PMC]

27.

Wan D, Villa D, Woods R, Yerushalmi R, Gelmon K. Breast Cancer Subtype Variation by Race and Ethnicity in a Diverse Population in British Columbia. Clin Breast Cancer. 2016;16:e49–55. [DOI] [PubMed]

28.

Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015;34:157–64. [DOI] [PubMed] [PMC]

29.

Kujtan LA, Morris S, Subramanian J. HER2 activity in solid tumors. JCO. 2017;35:e23121. [DOI]

30.

Gullo G, Walsh N, Fennelly D, Bose R, Walshe J, Tryfonopoulos D, et al. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project. Br J Cancer. 2018;119:374–80. [DOI] [PubMed] [PMC]

31.

Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23:1558–70. [DOI] [PubMed]

32.

Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22:1290–300. [DOI] [PubMed]

33.

Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20:518–30. [DOI] [PubMed] [PMC]

34.

Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, et al. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023;7:e2200609. [DOI] [PubMed]

35.

Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, et al. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study. J Clin Oncol. 2023;41:5569–78. [DOI] [PubMed] [PMC]

36.

Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, et al. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol. 2016;11:414–9. [DOI] [PubMed] [PMC]

37.

Skamene T, Siu LL, Renouf DJ, Laskin JJ, Bedard PL, Jones SJM, et al. Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial. JCO. 2018;36:TPS12127. [DOI]